Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2147-2156

  Zhao, Y ^a   Wu, N ^b   Chen, S ^b   Boulanger, L ^b   Police, R L ^b   Fraser, K ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Diabetic peripheral neuropathic pain; Duloxetine; Healthcare costs; Opioid use

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BUTORPHANOL; CODEINE; DEXTROPROPOXYPHENE; DIFLUNISAL; DULOXETINE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; INSULIN; LEVORPHANOL; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL ANTIDIABETIC AGENT; OXYCODONE; OXYMORPHINDOLE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PREGABALIN; SALSALATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DRUG COST; DRUG EFFICACY; DRUG USE; DRUG UTILIZATION; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NEUROPATHIC PAIN; OSTEOARTHRITIS; PATIENT CARE; PATIENT SELECTION; PRESCRIPTION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANALGESICS; ANALGESICS, OPIOID; DIABETIC NEUROPATHIES; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; UNITED STATES; YOUNG ADULT;

EID: 77955611521     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.503140     Document Type: Article

References (30)

1. Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med 2007;8(Suppl. 2):S27-32
2. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47:123-128
3. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
4. Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-1486
5. Boulton AJ. Management of Diabetic Peripheral Neuropathy, 23rd edn. 2005: 9-15
6. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-737
7. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag 2005;30:374-385
8. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68:1178-1182
9. Boulanger L, Zhao Y, Bao Y, et al. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res 2009;9:111
10. Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007;21:306-314
11. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900 (Pubitemid 44854739)
12. Currie CJ, Poole CD, Woehl A, et al. The health-related utility and healthrelated quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-2280
13. Boulanger L, Zhao Y, Foster TS, et al. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain. Curr Med Res Opin 2009;25:1763-1773
14. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;Suppl:3-19
15. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
16. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
17. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20
18. Jensen TS, Backonja MM, Hernandez JS, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:108-119
19. Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med 2007;8(Suppl. 2):S43-9
20. Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain 2008;9:1026-1035
21. Bureau of Labor Statistics. Consumer Price Index. January 2008. 2010
22. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for noncancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-449
23. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50: 105-116
24. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574
25. Afifi AA, Kotlerman JB, Ettner SL, et al. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007;28:95-111
26. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
27. Efron B, Tibhirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993
28. Gilson AM, Ryan KM, Joranson DE, et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manag 2004;28:176-188
29. Wu N, Chen S, Boulanger L, et al. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ 2009;12:192-202
30. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19(Suppl. 1):S16-21